Anti-Hu CD99 FITC

*Kueng HJ, Leb VM, Haiderer D, Raposo G, Thery C, Derdak SV, Schmetterer KG, Neunkirchner A, Sillaber C, Seed B, Pickl WF: General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol. 2007 Aug;81 (16) :8666-76., URL: http://www.ncbi.nlm.nih.gov/pubmed/17537846 , *Pickl WF, Pimentel-Muiñ os FX, Seed B: Lipid rafts and pseudotyping. J Virol. 2001 Aug;75 (15) :7175-83., URL: http://www.ncbi.nlm.nih.gov/pubmed/11435598 , *Brémond A, Meynet O, Mahiddine K, Coito S, Tichet M, Scotlandi K, Breittmayer JP, Gounon P, Gleeson PA, Bernard A, Bernard G: Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction. Blood. 2009 Jan 8;113 (2) :347-57., URL: http://www.ncbi.nlm.nih.gov/pubmed/18849489 , *Waclavicek M, Majdic O, Stulnig T, Berger M, Sunder-Plassmann R, Zlabinger GJ, Baumruker T, Stöckl J, Ebner C, Knapp W, Pickl WF: CD99 engagement on human peripheral blood T cells results in TCR/CD3-dependent cellular activation and allows for Th1-restricted cytokine production. J Immunol. 1998 Nov 1;161 (9) :4671-8., URL: http://www.ncbi.nlm.nih.gov/pubmed/9794396, *Weijler L, Kowarsch F, Wödlinger M, Reiter M, Maurer-Granofszky M, Schumich A, Dworzak MN: UMAP based anomaly detection for minimal residual disease quantification within acute myeloid leukemia. Cancers (Basel) 2022 Feb 11;14 (4) :898., URL: https://pubmed.ncbi.nlm.nih.gov/35205645/